This is a retrospective analysis of two different cohorts of patients that has undergone renal transplantation. This is a matched pair analysis of 100 patients treated with generic tacrolimus that will be compared with 100 matched controls treated with Prograf. Data will be obtained from patients' charts, from the Swedish National Kidney Registry and from a local registry at Transplantationscentrum. Patients included in the study are patients receiving a first single kidney transplant from a deceased or a living donor, treated with Prograf or Tacni and transplanted between transplanted January 2012 and August 2014. The 1-year-outcome of patients following renal transplantation, including BPAR, serious adverse effects and graft survival will be analysed.
Study Type
OBSERVATIONAL
Enrollment
186
Generic tacrolimus
Prograf, the original tacrolimus
Transplant Institute, Sahlgrenska University Hospital
Gothenburg, Sweden
Biopsy-proven acute rejection (BPAR)
Time frame: 1 year
Graft loss
Time frame: 1 year
Death
Time frame: 1 year
Compare the following parameters in the two groups • Graft survival at 6 and 12 months • BPAR at 6 and 12 months • Calculated GFR at 12 months
Time frame: 6 months, and 1 year
Compare serious adverse events at 12 months in the two groups
Time frame: 1 year
Compare the the cost of admissions for rejection treatment in the two groups
Time frame: 1 year
Tacrolimus dose at day of discharge
Time frame: day of discharge, approx 7 days
Tacrolimus levels at day of discharge
Time frame: day of discharge, approx 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.